Treating Patients with Complex Metabolic Conditions

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Year Invested: 2011
Location: Newton, Mass.

Recent News

December 2, 2019
Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria

January 4, 2019
Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019

November 7, 2018
Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

Read More News

Associated Team Members

Robert Tepper, M.D.